Cargando…
Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
BACKGROUND: Dysregulation of fibroblast growth factor receptor (FGFR) signaling pathway has been observed in head and neck squamous cell carcinoma (HNSCC) and is a promising therapeutic target for selective tyrosine kinase inhibitors (TKIs). Potential predictive biomarkers for response to FGFR-targe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693503/ https://www.ncbi.nlm.nih.gov/pubmed/34933671 http://dx.doi.org/10.1186/s13148-021-01212-4 |
_version_ | 1784619153198415872 |
---|---|
author | Bao, Yilin Gabrielpillai, Jennis Dietrich, Jörn Zarbl, Romina Strieth, Sebastian Schröck, Friederike Dietrich, Dimo |
author_facet | Bao, Yilin Gabrielpillai, Jennis Dietrich, Jörn Zarbl, Romina Strieth, Sebastian Schröck, Friederike Dietrich, Dimo |
author_sort | Bao, Yilin |
collection | PubMed |
description | BACKGROUND: Dysregulation of fibroblast growth factor receptor (FGFR) signaling pathway has been observed in head and neck squamous cell carcinoma (HNSCC) and is a promising therapeutic target for selective tyrosine kinase inhibitors (TKIs). Potential predictive biomarkers for response to FGFR-targeted therapies are urgently needed. Understanding the epigenetic regulation of FGF pathway related genes, i.e. FGFRs, FGFs, and CCND1, could enlighten the way towards biomarker-selected FGFR-targeted therapies. METHODS: We performed DNA methylation analysis of the encoding genes FGFR1, FGFR2, FGFR3, FGFR4, FGF1-14, FGF16-23, and CCND1 at single CpG site resolution (840 CpG sites) employing The Cancer Genome Research Atlas (TCGA) HNSCC cohort comprising N = 530 tumor tissue and N = 50 normal adjacent tissue samples. We correlated DNA methylation to mRNA expression with regard to human papilloma virus (HPV) and gene amplification status. Moreover, we investigated the correlation of methylation with sensitivity to the selective FGFR inhibitors PD 173074 and AZD4547 in N = 40 HPV(−) HNSCC cell lines. RESULTS: We found sequence-contextually nuanced CpG methylation patterns in concordance with epigenetically regulated genes. High methylation levels were predominantly found in the promoter flank and gene body region, while low methylation levels were present in the central promoter region for most of the analyzed CpG sites. FGFRs, FGFs, and CCND1 methylation differed significantly between tumor and normal adjacent tissue and was associated with HPV and gene amplification status. CCND1 promoter methylation correlated with CCND1 amplification. For most of the analyzed CpG sites, methylation levels correlated to mRNA expression in tumor tissue. Furthermore, we found significant correlations of DNA methylation of specific CpG sites with response to the FGFR1/3–selective inhibitors PD 173074 and AZD4547, predominantly within the transcription start site of CCND1. CONCLUSIONS: Our results suggest an epigenetic regulation of CCND1, FGFRs, and FGFs via DNA methylation in HNSCC and warrants further investigation of DNA methylation as a potential predictive biomarker for response to selective FGFR inhibitors in clinical trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01212-4. |
format | Online Article Text |
id | pubmed-8693503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86935032021-12-23 Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors Bao, Yilin Gabrielpillai, Jennis Dietrich, Jörn Zarbl, Romina Strieth, Sebastian Schröck, Friederike Dietrich, Dimo Clin Epigenetics Research BACKGROUND: Dysregulation of fibroblast growth factor receptor (FGFR) signaling pathway has been observed in head and neck squamous cell carcinoma (HNSCC) and is a promising therapeutic target for selective tyrosine kinase inhibitors (TKIs). Potential predictive biomarkers for response to FGFR-targeted therapies are urgently needed. Understanding the epigenetic regulation of FGF pathway related genes, i.e. FGFRs, FGFs, and CCND1, could enlighten the way towards biomarker-selected FGFR-targeted therapies. METHODS: We performed DNA methylation analysis of the encoding genes FGFR1, FGFR2, FGFR3, FGFR4, FGF1-14, FGF16-23, and CCND1 at single CpG site resolution (840 CpG sites) employing The Cancer Genome Research Atlas (TCGA) HNSCC cohort comprising N = 530 tumor tissue and N = 50 normal adjacent tissue samples. We correlated DNA methylation to mRNA expression with regard to human papilloma virus (HPV) and gene amplification status. Moreover, we investigated the correlation of methylation with sensitivity to the selective FGFR inhibitors PD 173074 and AZD4547 in N = 40 HPV(−) HNSCC cell lines. RESULTS: We found sequence-contextually nuanced CpG methylation patterns in concordance with epigenetically regulated genes. High methylation levels were predominantly found in the promoter flank and gene body region, while low methylation levels were present in the central promoter region for most of the analyzed CpG sites. FGFRs, FGFs, and CCND1 methylation differed significantly between tumor and normal adjacent tissue and was associated with HPV and gene amplification status. CCND1 promoter methylation correlated with CCND1 amplification. For most of the analyzed CpG sites, methylation levels correlated to mRNA expression in tumor tissue. Furthermore, we found significant correlations of DNA methylation of specific CpG sites with response to the FGFR1/3–selective inhibitors PD 173074 and AZD4547, predominantly within the transcription start site of CCND1. CONCLUSIONS: Our results suggest an epigenetic regulation of CCND1, FGFRs, and FGFs via DNA methylation in HNSCC and warrants further investigation of DNA methylation as a potential predictive biomarker for response to selective FGFR inhibitors in clinical trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01212-4. BioMed Central 2021-12-21 /pmc/articles/PMC8693503/ /pubmed/34933671 http://dx.doi.org/10.1186/s13148-021-01212-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bao, Yilin Gabrielpillai, Jennis Dietrich, Jörn Zarbl, Romina Strieth, Sebastian Schröck, Friederike Dietrich, Dimo Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors |
title | Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors |
title_full | Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors |
title_fullStr | Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors |
title_full_unstemmed | Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors |
title_short | Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors |
title_sort | fibroblast growth factor (fgf), fgf receptor (fgfr), and cyclin d1 (ccnd1) dna methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (hpv) status, and sensitivity to tyrosine kinase inhibitors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693503/ https://www.ncbi.nlm.nih.gov/pubmed/34933671 http://dx.doi.org/10.1186/s13148-021-01212-4 |
work_keys_str_mv | AT baoyilin fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors AT gabrielpillaijennis fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors AT dietrichjorn fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors AT zarblromina fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors AT striethsebastian fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors AT schrockfriederike fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors AT dietrichdimo fibroblastgrowthfactorfgffgfreceptorfgfrandcyclind1ccnd1dnamethylationinheadandnecksquamouscellcarcinomasisassociatedwithtranscriptionalactivitygeneamplificationhumanpapillomavirushpvstatusandsensitivitytotyrosinekinaseinhibitors |